Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference
Larimar Therapeutics (Nasdaq: LRMR) announced that CEO Carole Ben-Maimon will present at the JMP Securities Life Sciences Conference on June 16-17, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Larimar Therapeutics (Nasdaq: LRMR) announced that CEO Carole Ben-Maimon will present at the JMP Securities Life Sciences Conference on June 16-17, 2021. The presentation will take the form of a fireside chat scheduled for 2:00 PM ET on June 16. Larimar focuses on developing treatments for rare diseases, currently evaluating its lead compound, CTI-1601, in a Phase 1 clinical program for Friedreich’s ataxia. The company aims to utilize its platform for creating fusion proteins targeting additional rare diseases.
Details
News Market Reaction – LRMR
The recorded move for LRMR in the trading session of this news was -0.72%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BALA CYNWYD, Pa., June 11, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar Therapeutics, will present and participate in virtual 1x1 investor meetings at the JMP Securities Life Sciences Conference taking place from June 16-17, 2021. See below for more details.
| Presentation Format: | Fireside chat |
| Date: | June 16, 2021 |
| Time: | 2:00 PM ET |
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the U.S. as a potential treatment for Friedreich’s ataxia (FA). Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569
Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.